Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- University of Cambridge
- Autonomous University of Madrid (Universidad Autónoma de Madrid)
- Fundación Investigación del Cáncer Universidad de Salamanca
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- IBIMA Plataforma BIONAND
- Purdue University
- SciLifeLab
- The University of Chicago
- University of Mainz
- Université Paris Cité
-
Field
-
Supervisor: Dr Tim Halim Course start date: 1st October 2027 Project details For further information about the research group, please visit our website at https://www.cruk.cam.ac.uk/research-groups
-
benefit while sparing those unlikely to respond from their toxicities remains a major challenge. Many modern therapies, like immunotherapy and ADCs, rely on tissue architecture to be effective
-
cancers worldwide despite major advances in immunotherapy. A major obstacle is the profound immunosuppressive tumor microenvironment that progressively disables anti-tumor immune responses. Natural Killer
-
-Oncology by leading projects aimed at developing therapeutic strategies that enhance innate immunity against cancers that are refractory to immunotherapy. The appointees will be expected to build internal
-
murine models, aiming to characterize the efficacy and safety of the CAR-T constructs developed against rhabdoid tumor cells. Where to apply Website https://www.uam.es/uam/investigacion/ofertas-empleo
-
multimodal algorithm of epigenetic blood predictors of the clinical benefit of SBRT in immunotherapy-resistant tumors Research Line: IBIMA-BE-17 CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH IN RADIATION
-
) at Uppsala University and SciLifeLab , the national infrastructure for life science. Project description Immunotherapy has become a life-saving option for advanced cancer patients. However, only a minority of
-
immunotherapy. Possible project elements include: Artificial cells that process cytokine signals or re-establish tissue homeostasis Synthetic signaling hubs for tumor-microenvironment models Reporter cell assays
-
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt | Germany | 3 months ago
drive metabolic disorders and to translate these insights into precise, context-specific immunotherapies. Ultimately, we strive to develop strategies that modulate immune responses while supporting tissue
-
) (HORIZON-ERC) (ERCEA/C/04) “Next-generation colorectal cancer microecosystems for the discovery of microbiome-driven immunotherapies in personalized settings”, whose responsible person is Luis Francisco